- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Jonathan Campbell, PhD: Value-Based Contracts and Biosimilars
Jonathan Campbell, PhD, associate professor, Department of Clinical Pharmacy, Pharmaceutical Outcomes Research, Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of Colorado, discusses whether value-based contracts have a role to play in biosimilar uptake.
Transcript
For biosimilars, outcomes-base contracting may be very important in terms of guarantees for certain health outcomes, like a measure of response of the patient. So that could be certainly something in a broad understanding of value that’s very interesting, so it could certainly apply to biosimilars as well.
Newsletter
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.
